IRIS
GUERRA, TOMMASO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 191
EU - Europa 116
AS - Asia 40
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 350
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 187
IT - Italia 36
SE - Svezia 28
SG - Singapore 25
DE - Germania 17
CN - Cina 13
FI - Finlandia 8
CZ - Repubblica Ceca 6
BE - Belgio 5
GB - Regno Unito 5
CA - Canada 4
FR - Francia 3
PT - Portogallo 3
A1 - Anonimo 2
IN - India 2
NL - Olanda 2
AR - Argentina 1
GR - Grecia 1
LT - Lituania 1
UA - Ucraina 1
Totale 350
Salva come PNG Salva come JPEG
Città #
Chandler 60
Nyköping 25
Singapore 21
Fairfield 13
Munich 12
Ashburn 11
Helsinki 8
New York 8
Houston 6
Lawrence 6
Brno 5
Brussels 5
Roxbury 5
Seattle 5
Bari 4
Woodbridge 4
Bisceglie 3
Cambridge 3
Des Moines 3
Wilmington 3
Boardman 2
Guangzhou 2
Ottawa 2
Paris 2
Terlan 2
Toronto 2
Ann Arbor 1
Beijing 1
Brooklyn 1
Foshan 1
Frankfurt am Main 1
General Pacheco 1
Grafing 1
Imbersago 1
Indianapolis 1
Inglewood 1
Jiaxing 1
Jinhua 1
Kilburn 1
London 1
Los Angeles 1
Marseille 1
Milan 1
Naples 1
New Delhi 1
Olomouc 1
Princeton 1
Pune 1
Redwood City 1
Santa Clara 1
Triggiano 1
Wuhan 1
Totale 248
Salva come PNG Salva come JPEG
Nome #
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 66
Dengue fever in a multiple sclerosis patient taking Ocrelizumab 52
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 49
Anti Th/To autoantibodies: a predictor markers for interstitial lung disease in undifferentiated connective tissue disease at risk of systemic sclerosis 47
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 39
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 32
null 21
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 15
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register 12
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register 12
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry 7
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 6
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 5
Multiple Sclerosis Progression and Relapse Activity in Children 5
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 1
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series 1
Totale 370
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.905
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.905
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 1 1 0 1 0 0 1
2020/202132 0 0 0 7 4 1 0 3 4 4 7 2
2021/202258 4 10 3 0 3 4 0 6 1 5 8 14
2022/2023116 17 18 6 16 10 11 3 11 18 1 4 1
2023/202481 6 11 2 5 13 14 4 2 1 2 4 17
2024/202579 20 16 15 16 12 0 0 0 0 0 0 0
Totale 370